AGIO: Agios Pharmaceuticals Company Short-Term Debt

Symbol and logo of brand Agios Pharmaceuticals (AGIO)

A strong patent shield and high R&D expenditures provide Agios Pharmaceuticals (AGIO) with long-term resilience. The volume of short loans confirms this stability, and this metric equals 0.02. Business efficiency is based on AI-driven metabolism modeling to accelerate clinical trials, as well as the recruitment of leading biologists through generous funding of fundamental discoveries.

AGIO (Agios) Company Short-Term Debts history from 07/04/2022 to 10/30/2026

AGIO (Agios Corp): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Agios Pharmaceuticals, Inc.|AGIO - Fair Value Consensus
- market capitalization information:
Market Value Agios Pharmaceuticals, Inc.|AGIO - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Agios Pharmaceuticals|AGIO - Book Capitalization|Market Cap to Net Assets Ratio agios.com|AGIO - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Agios Pharmaceuticals|AGIO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Agios Pharmaceuticals|AGIO - Company Cumulative Debt|Debt to Book Value Agios Pharmaceuticals, Inc.|AGIO - Amount of Long-Term Liabilities|Company Short-Term Debts Agios Pharmaceuticals|Quick Ratio agios.com
- net income and valuation multiples indicators:
AGIO - Company Net Income
Basic company analysis:Agios Pharmaceuticals, Inc. - AGIO
Mass-produced product of Agios Corp

Short-term debt reflects the aggregate of obligations with a maturity of up to one year, allowing for the real-time tracking of liquidity dynamics and default risk through credit obligations under one year. This metric measures the ability of Agios Pharmaceuticals (AGIO) to service current loans, which is critical for sustaining R&D activity leveraged by its proprietary leadership in metabolic therapy and revenues from the sale of rights to legacy drugs.

Who Agios Pharmaceuticals competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt NewAmsterdam Pharma N.V. NAMS|SLNO - Company Current Liabilities|Amicus Therapeutics - Company Short-Term Debts|Short-Term Debt 89bio.com|GPCR (Structure Therapeutics Inc.) - Company Current Liabilities|MDXG: Amount of Current Liabilities|RZLT (Rezolute Corp) - Company Short-Term Debts|Company Short-Term Debts Lexicon Corp|Company Short-Term Debts MBX|Company Short-Term Debt ALT (altimmune.com)|Company Short-Term Debt Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. (SGMT) - Short-Term Debt|BIOA - Company Short-Term Debt|BMEA: Company Short-Term Debt|QNCX: Company Short-Term Debts|GUTS - Short-Term Debt Volume|Company Short-Term Debt vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Short-Term Debt Volume|Company Short-Term Debt Pluri Inc. (PLUR)|Company Current Liabilities synlogictx.com SYBX|Company Short-Term Debts LPCN (Lipocine Inc.)|Company Short-Term Debts Matinas BioPharma Holdings, Inc. MTNB|Spruce Biosciences - Company Short-Term Debts|Short-Term Indebtedness Galecto Inc (GLTO)|CTCX: Company Short-Term Debts|LUMO - Short-Term Debt Volume|Company Short-Term Debt Organovo Holdings, Inc.|Short-Term Debt radiuspharm.com RDUS